FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Continues to Review Ocaliva sNDA

FDA says it is continuing to review the sNDA submitted by Intercept Pharmaceuticals for its Ocaliva following an advisory committee 10-1 vote not to r...

latest-news-card-1
Human Drugs

AbbVie NDA for Parkinsons Drug Approved

FDA approves an AbbVie NDA for Vyalev (foscarbidopa and foslevodopa), a subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced ...

latest-news-card-1
Human Drugs

Guide on Postoperative Nausea/Vomiting Drugs

FDA posts a draft guidance entitled Postoperative Nausea and Vomiting: Developing Drugs for Prevention.

latest-news-card-1
Federal Register

Comments Extended on Conformance Assessment Program

Federal Register notice: FDA extends the comment period on a 9/23 notice about three draft guidance documents related to CDRHs Accreditation Scheme fo...

latest-news-card-1
Human Drugs

FDA Wants Integrated Drug Review Feedback

Attorney Deborah Livornese says FDA wants user feedback on the NDA integrated review format it has been publishing for several years.

latest-news-card-1
Federal Register

Guide on ANDA Reconsideration Requests

Federal Register notice: FDA makes available a final guidance requesting the reconsideration of an ANDA decision at the division level.

latest-news-card-1
Human Drugs

Staska Pharma Recalls Ascorbic Acid Solution

Staska Pharmaceuticals recalls one lot of ascorbic acid solution for injection (500mg/mL, 50mL vials) due to the presence of glass particulates in som...

latest-news-card-1
Human Drugs

Cancer Trial Core Patient-Reported Outcomes Guide

FDA publishes a guidance with recommendations for collecting a core set of patient-reported clinical outcomes in cancer clinical trials.

Biologics

FDA Holds Novavax Covid/Flu Vaccine IND

FDA places a clinical hold on the Novavax IND for a Covid-19/influenza combination vaccine and influenza standalone vaccine following a report of one ...

latest-news-card-1
Human Drugs

GDUFA Division Level Reconsideration Request

FDA publishes a guidance reflecting GDUFA 3 provisions on the procedures for ANDA applicants to follow in requesting reconsideration of scientific iss...